指南与共识甲状腺与浅表头颈US

ACR-TIRADS、美国甲状腺协会(ATA)与EU-TIRADS指南检测甲状腺恶性病变诊断准确性的比较

Comparison of diagnostic accuracy of ACR-TIRADS, American Thyroid Association (ATA), and EU-TIRADS guidelines in detecting thyroid malignancy.
指南 / 共识 · Eur J Radiol · 2020-11-02

本研究纳入540例患者共597个甲状腺结节,按ATA-2015、ACR-TIRADS和EU-TIRADS三种指南对超声图像分类评分,以细针穿刺活检Bethesda细胞病理结果为参考,比较三种指南的诊断准确性。ACR-TIRADS准确率最高(59.93%),ATA-2015为55.20%,EU-TIRADS为51.25%;敏感度与特异度分别为ATA-2015(82.22、53.47)、ACR-TIRADS(48.89、60.63)、EU-TIRADS(86.67、48.99)。作者结论认为不同指南的诊断强度、不必要的推荐FNAB率和分类能力存在差异。

要点

  • 以Bethesda细胞病理为参考,ACR-TIRADS准确率59.93%高于ATA-2015的55.20%和EU-TIRADS的51.25%。
  • 按各指南专属FNAB标准,ATA-2015可诊断38个恶性结节,ACR-TIRADS为34个,EU-TIRADS为31个。
  • ATA-2015有23个结节(3.8%)无法分类。

核心结论

  • 不同指南的诊断强度、不必要的推荐FNAB率和分类能力存在差异,临床医生和介入放射科医生在处理甲状腺结节时应牢记这些特征。

研究设计与样本

  • 本研究为指南比较研究,共纳入540例患者、597个甲状腺结节。
  • 对超声图像按ATA-2015、ACR-TIRADS和EU-TIRADS三种指南进行分类和评分。
  • 行细针穿刺活检(FNAB),细胞病理结果按Bethesda系统报告,并将三种分类系统的结果与Bethesda结果进行关联分析。

诊断标准与关键数值

  • FNAB结果共显示447个良性结节和45个恶性结节。
  • 按各指南专属FNAB标准,ATA-2015可诊断38个恶性结节,ACR-TIRADS为34个,EU-TIRADS为31个。
  • 按各指南专属FNAB标准,ATA-2015会对301个良性结节进行活检,ACR-TIRADS为143个,EU-TIRADS为222个。
  • 准确率ACR-TIRADS最高为59.93%,ATA-2015为55.20%,EU-TIRADS为51.25%。
  • 敏感度与特异度分别为ATA-2015(82.22、53.47)、ACR-TIRADS(48.89、60.63)、EU-TIRADS(86.67、48.99)。

临床应用与阅片要点

  • 作者结论指出,临床医生和介入放射科医生在处理甲状腺结节时应牢记各指南在诊断强度、不必要的推荐FNAB率和分类能力上的差异。
  • ATA-2015有23个结节(3.8%)无法分类,报告时需注意该指南的分类覆盖限制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aims to compare three guidelines according to their diagnostic accuracy in the management of thyroid nodules.

METHODS: A total of 540 patients with 597 thyroid nodules were enrolled in this study. Sonographic images were classified and scored with the American Thyroid Association (ATA-2015), American College of Radiology (ACR), and European Thyroid Association (EU) Thyroid Imaging, Reporting, and Data Systems (ACR-TIRADS and EU-TIRADS) guidelines. Fine-needle aspiration biopsy (FNAB) was performed, and cytopathological results were reported with the Bethesda system. Outcomes of these three classification systems were then correlated with Bethesda results.

RESULTS: FNAB procedures revealed a total of 447 benign and 45 malignant nodules. With guideline dedicated FNAB criteria; 38 malignant nodules could have been diagnosed with ATA-2015, which is followed by 34 nodules with ACR-TIRADS, and 31 nodules with EU-TIRADS. Nonetheless, 301 benign nodules would have been biopsied with ATA-2015, 143 benign nodules with ACR-TIRADS, 222 benign nodules with EU-TIRADS. The accuracy rate was found to be highest with ACR-TIRADS (59.93 %); while 55.20 % with ATA-2015 and 51.25 % with EU-TIRADS. The sensitivity and specificity ratios of these guidelines were as follows; ATA-2015 (82.22, 53.47), ACR-TIRADS (48.89, 60.63), and EU-TIRADS (86.67, 48.99). A total of 23 nodules (3.8 %) could not be classified with ATA-2015.

CONCLUSION: Diagnostic strengths, unnecessary recommended FNAB rates, and categorization capabilities differ among various guidelines. Clinicians and interventional radiologists should keep in mind these features in the management of thyroid nodules.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Koc AM, Adıbelli ZH, Erkul Z, et al. Comparison of diagnostic accuracy of ACR-TIRADS, American Thyroid Association (ATA), and EU-TIRADS guidelines in detecting thyroid malignancy. Eur J Radiol. 2020. PMID: 33181485. doi:10.1016/j.ejrad.2020.109390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。